Hints and tips:
Related Special Reports
...Ryan Richardson, chief strategy officer at BioNTech, said the company was focused on the mid-to-long term and that most of the shareholders were long-term investors....
...It is hard to see how he can climb out of the morass without selling or spinning off the company’s consumer health division, despite Bayer long resisting calls for a break-up....
...“A lot of people saw the telemedicine component as an antidote to WeightWatchers’ foes, but I saw a very competitive market that they were entering,” said Stephanie Davis, a healthcare technology analyst...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Successfully implemented at the helm of Genentech, this rid the months-long process to allocate budgets and freed up funds to be spent on innovation. “I’ve seen it before....
...Regeneron is in a long-running legal dispute with Amgen centred on accusations the company violated antitrust laws in the way it marketed a cholesterol drug....
...The biotech sector has been particularly hard hit by the IPO freeze, as early-stage companies rely on equity sales to fund long and expensive drug developments....
...The world’s biggest healthcare products company said on Tuesday it was unfortunate that it had to pay claimants for what it described as “baseless scientific claims” but noted that protracted litigation...
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...The pharmaceutical giants AbbVie and Eli Lilly have pulled out of the UK’s pricing agreement with the NHS. Bayer’s pharmaceutical arm is reducing its UK footprint and cutting jobs....
...Healthcare should not be like this, and would not be if the patent system worked as intended....
...Bayer, one of the largest suppliers of conventional contraceptives in the US market, has said a fall in new prescriptions of birth control pills and long-acting IUDs has caused a decline in the overall market...
...Over the medium to long term, the market for this new class of GLP-1 drugs is expected to become fiercely competitive as rival pharmaceutical companies launch new therapies....
...But the National Healthcare Security Administration, which negotiates drug prices for China’s national health insurance reimbursement scheme, balked at the “high price” quoted by Pfizer....
...Bayer shuns ‘innovation unfriendly’ Europe The German pharmaceutical company has said it is shifting the focus of its drugs business to the US and away from Europe, where governments are making “big mistakes...
...However, large pharmaceutical and healthcare companies — including those such as J&J that have benefited from the cash generated by Covid-19 vaccine sales — have been in a better position to strike deals...
...Gabriel Harnier group general counsel, BAYER Three years ago, under Harnier’s leadership, the legal team at Bayer, the German pharmaceuticals and life sciences company, moved its contracting, data privacy...
...Following the publication of trial data, he apologised for the long delay in developing lecanemab....
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
...of healthcare and the pharmaceutical sectors....
...Johnson & Johnson is to spin off its consumer products division, best known for Band-Aids and baby shampoo, as the world’s largest healthcare company seeks to focus on pharmaceuticals and medical devices...
...The original high price reignited a long-simmering debate over how to address the cost of medicines in the US....
...J&J is following a trend in the pharmaceutical sector, as companies dispose of slower growing consumer healthcare divisions to concentrate on drug discovery....
...The world’s largest healthcare company plans to split itself in two....
International Edition